Philip Nickson
General Counsel bei MONTE ROSA THERAPEUTICS, INC.
Vermögen: - $ am 31.05.2024
Aktive Positionen von Philip Nickson
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| MONTE ROSA THERAPEUTICS, INC. | General Counsel | 01.03.2021 | - |
Karriereverlauf von Philip Nickson
Ehemalige bekannte Positionen von Philip Nickson
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| MOMENTA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.01.2012 | 01.03.2021 |
Ausbildung von Philip Nickson
| Suffolk University | Graduate Degree |
| The University of Manchester | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 4 |
| Israel | 2 |
Operativ
| General Counsel | 1 |
| Corporate Officer/Principal | 1 |
| Graduate Degree | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| MONTE ROSA THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Momenta Pharmaceuticals, Inc.
 Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
- Börse
- Insiders
- Philip Nickson
- Erfahrung